COMPASS Pathways (CMPS) Stock Forecast & Price Target

Compare

2,191 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CMPS Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

COMPASS

Pathways

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CMPS Stock 12 Month Forecast

Average Price Target

$17.67

▲(131.89% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $17.67 with a high forecast of $40.00 and a low forecast of $8.00. The average price target represents a 131.89% change from the last price of $7.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","11":"$11","21":"$21","31":"$31","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,11,21,31,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.9,9.446153846153846,11.992307692307694,14.53846153846154,17.084615384615386,19.630769230769232,22.17692307692308,24.723076923076924,27.269230769230774,29.815384615384616,32.361538461538466,34.90769230769231,37.45384615384616,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.9,7.728461538461539,8.556923076923077,9.385384615384616,10.213846153846156,11.042307692307693,11.870769230769232,12.69923076923077,13.527692307692309,14.356153846153848,15.184615384615386,16.013076923076923,16.841538461538462,{"y":17.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.9,6.984615384615385,7.06923076923077,7.153846153846154,7.2384615384615385,7.323076923076924,7.407692307692308,7.492307692307692,7.576923076923077,7.661538461538462,7.746153846153846,7.830769230769231,7.915384615384616,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.78,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.77,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$17.67

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$40

Buy

424.93%

Upside

Reiterated

01/09/26

Advancing COMP360 From Binary Clinical Risk to Scaled Commercial Opportunity: Buy Rating Reaffirmed on De-Risked TRD Launch and PTSD Upside

Paul Matteis

Stifel Nicolaus

$11

Buy

44.36%

Upside

Reiterated

01/08/26

Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)

Joshua Schimmer

Cantor Fitzgerald

$20

Buy

162.47%

Upside

Reiterated

01/07/26

Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Leonid Timashev

RBC Capital

$16

Buy

109.97%

Upside

Reiterated

01/07/26

RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

Thomas Shrader

BTIG

$14

Buy

83.73%

Upside

Reiterated

01/07/26

De-Risked Clinical Profile and Growing Commercial Infrastructure Support Buy Rating on COMPASS Pathways’ COMP360

Gavin Clark-Gartner

Evercore ISI

Hold

4.99%

Upside

Reiterated

12/18/25

COMPASS Pathways (CMPS) Receives a Hold from Evercore ISI

Jay Olson

Oppenheimer

$15

Buy

96.85%

Upside

Initiated

12/10/25

Compass Pathways upgraded to Outperform from Perform at OppenheimerCompass Pathways upgraded to Outperform from Perform at Oppenheimer

Michael Okunewitch

Maxim Group

$12

Buy

57.48%

Upside

Reiterated

11/07/25

Buy Rating for COMPASS Pathways: Accelerated Clinical Development and Strategic Position in Mental Health Sector

Ritu Baral

TD Cowen

$23

Buy

201.84%

Upside

Reiterated

11/04/25

Accelerated Phase 3 Timeline and Strong Financials Boost COMPASS Pathways' Prospects

Sumant Kulkarni

Canaccord Genuity

$15

Buy

96.85%

Upside

Reiterated

08/14/25

Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support

Judah Frommer

Morgan Stanley

$10

Buy

31.23%

Upside

Initiated

08/08/25

COMPASS Pathways (CMPS) Receives a New Rating from Morgan Stanley

Elemer Piros

Lucid Capital

$30→$9

Buy

18.11%

Upside

Reiterated

01/27/25

Compass Pathways (CMPS) PT Lowered to $9 at Rodman RenshawRodman Renshaw analyst Elemer Piros lowered the price target on Compass Pathways (NASDAQ: CMPS) to $9.00 (from $30.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$40

Buy

424.93%

Upside

Reiterated

01/09/26

Advancing COMP360 From Binary Clinical Risk to Scaled Commercial Opportunity: Buy Rating Reaffirmed on De-Risked TRD Launch and PTSD Upside

Paul Matteis

Stifel Nicolaus

$11

Buy

44.36%

Upside

Reiterated

01/08/26

Stifel Nicolaus Remains a Buy on COMPASS Pathways (CMPS)

Joshua Schimmer

Cantor Fitzgerald

$20

Buy

162.47%

Upside

Reiterated

01/07/26

Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Leonid Timashev

RBC Capital

$16

Buy

109.97%

Upside

Reiterated

01/07/26

RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

Thomas Shrader

BTIG

$14

Buy

83.73%

Upside

Reiterated

01/07/26

De-Risked Clinical Profile and Growing Commercial Infrastructure Support Buy Rating on COMPASS Pathways’ COMP360

Gavin Clark-Gartner

Evercore ISI

Hold

4.99%

Upside

Reiterated

12/18/25

COMPASS Pathways (CMPS) Receives a Hold from Evercore ISI

Jay Olson

Oppenheimer

$15

Buy

96.85%

Upside

Initiated

12/10/25

Compass Pathways upgraded to Outperform from Perform at OppenheimerCompass Pathways upgraded to Outperform from Perform at Oppenheimer

Michael Okunewitch

Maxim Group

$12

Buy

57.48%

Upside

Reiterated

11/07/25

Buy Rating for COMPASS Pathways: Accelerated Clinical Development and Strategic Position in Mental Health Sector

Ritu Baral

TD Cowen

$23

Buy

201.84%

Upside

Reiterated

11/04/25

Accelerated Phase 3 Timeline and Strong Financials Boost COMPASS Pathways' Prospects

Sumant Kulkarni

Canaccord Genuity

$15

Buy

96.85%

Upside

Reiterated

08/14/25

Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support

Judah Frommer

Morgan Stanley

$10

Buy

31.23%

Upside

Initiated

08/08/25

COMPASS Pathways (CMPS) Receives a New Rating from Morgan Stanley

Elemer Piros

Lucid Capital

$30→$9

Buy

18.11%

Upside

Reiterated

01/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COMPASS Pathways

3 Months

xxx

Success Rate

8/13 ratings generated profit

Average Return

+6.41%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +6.41% per trade.

1 Year

Leonid TimashevRBC Capital

Success Rate

6/10 ratings generated profit

Average Return

+33.47%

reiterated a buy rating 6 days ago

Copying Leonid Timashev's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +33.47% per trade.

2 Years

xxx

Success Rate

9/10 ratings generated profit

Average Return

+49.02%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +49.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMPS Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CMPS has received 12 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. CMPS average Analyst price target in the past 3 months is 17.67.

Each month's total comprises the sum of three months' worth of ratings.

CMPS Financial Forecast

CMPS Earnings Forecast

Next quarter’s earnings estimate for CMPS is -$0.40 with a range of -$0.56 to -$0.08. The previous quarter’s EPS was -$1.44. CMPS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CMPS has Performed in-line its overall industry.

No data currently available

CMPS Sales Forecast

Next quarter’s sales forecast for CMPS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CMPS has Performed in-line its overall industry.

CMPS Stock Forecast FAQ

What is CMPS’s average 12-month price target, according to analysts?

Based on analyst ratings, COMPASS Pathways’s 12-month average price target is 17.67.

What is CMPS’s upside potential, based on the analysts’ average price target?

COMPASS Pathways has 131.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CMPS a Buy, Sell or Hold?

COMPASS Pathways has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is COMPASS Pathways’s price target?

The average price target for COMPASS Pathways is 17.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $8.00. The average price target represents 131.89% Increase from the current price of $7.62.

What do analysts say about COMPASS Pathways?

COMPASS Pathways’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of CMPS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

COMPASS Pathways (CMPS) Stock Forecast & Price Target

CMPS Analyst Ratings

CMPS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering COMPASS Pathways

CMPS Analyst Recommendation Trends

CMPS Financial Forecast

CMPS Earnings Forecast

CMPS Sales Forecast

CMPS Stock Forecast FAQ

Detailed List of Analyst Forecasts